title: A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.
abstract: The interim results of the nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease are reported. Four years ago, two prospective clinical studies were started to evaluate the long-term effects of bromocriptine in Parkinson's disease. The first was to investigate the long-term effects of bromocriptine monotherapy and the second to see the long-term effects of a combination therapy of bromocriptine with levodopa. Patients who had never been treated with levodopa were placed on bromocriptine monotherapy, and those who had been treated with levodopa for not more than 5 years were allocated randomly to either the combination or the levodopa group. Two hundred and eighty-six patients were enrolled in the former study and 416 in the latter. Among the 286 patients, 164 continued for further observation at the end of the fourth year, and 74 of them were still being treated with bromocriptine monotherapy. However, in 78, levodopa had to be added. Among the 416 patients in the second study, 216 were allocated to the combination group and 200 to the levodopa control group. At the end of the fourth year, 130 in the former and 140 in the latter group remained for further observation. In all three groups, a gradual loss of efficacy was noted. The rate of efficacy loss appeared largest in the monotherapy group and smallest in the combination group. Effects on tremor and rigidity are still maintained, but effects on akinesia and gait were lost by the end of the fourth year in all groups. Wearing-off and dyskinesias seem to be better managed by the combination therapy. The incidence of wearing-off was very small in the monotherapy group. No serious side effects were encountered except for 1 patient who died of pulmonary fibrosis in the combination group.
authors.affiliation: Department of Neurology, Mishuku Hospital, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuno
authors.forename: I
authors.initials: I
authors.lastname: Goto
authors.forename: M
authors.initials: M
authors.lastname: Iwata
authors.forename: I
authors.initials: I
authors.lastname: Kanazawa
authors.forename: H
authors.initials: H
authors.lastname: Kowa
authors.forename: T
authors.initials: T
authors.lastname: Mannen
authors.forename: H
authors.initials: H
authors.lastname: Nishitani
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
mesh_terms: D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008134:Long-Term Care; D009048:Motor Skills / Q000187:drug effects; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D001971:Bromocriptine; D007980:Levodopa